Nicholas Corcoran net worth and biography

Nicholas Corcoran Biography and Net Worth

Insider of TransMedics Group

Nick Corcoran joins TransMedics with over 20 years of experience in global supply chain and commercial operations. Prior to joining TransMedics, Mr. Corcoran served multiple roles of increasing responsibility at Stryker Corporation. Most recently, Mr. Corcoran served as Vice President of Division Operations for Stryker Joint Replacement, managing the division’s entire supply chain, including internal manufacturing sites and external supply partners. Earlier in his career at Stryker, Mr. Corcoran served as Vice President of Division and Commercial Operations for the Spine Division, Senior Director of Division Operations, and Director of Global Sourcing. He also held a variety of Supply Chain and Operations roles at Waters Corporation and Intel Corporation. Mr. Corcoran holds a bachelor’s degree in Finance and Economics from South East Technological University and a Master’s of Business in Supply Chain Management from The Smurfit School of Business, University College Dublin.

What is Nicholas Corcoran's net worth?: The estimated net worth of Nicholas Corcoran is at least $3.40 million as of March 2nd, 2026. Mr. Corcoran owns 29,831 shares of TransMedics Group stock worth more than $3,400,734 as of April 10th. This net worth estimate does not reflect any other investments that Mr. Corcoran may own. Learn More about Nicholas Corcoran's net worth.
How do I contact Nicholas Corcoran?: The corporate mailing address for Mr. Corcoran and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Nicholas Corcoran's contact information.
Has Nicholas Corcoran been buying or selling shares of TransMedics Group?: Nicholas Corcoran has not been actively trading shares of TransMedics Group over the course of the past ninety days. Most recently, Nicholas Corcoran sold 2,966 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $139.12, for a transaction totalling $412,629.92. Following the completion of the sale, the insider now directly owns 29,831 shares of the company's stock, valued at $4,150,088.72. Learn More on Nicholas Corcoran's trading history.
Who are TransMedics Group's active insiders?: TransMedics Group's insider roster includes John Carey (VP), Nicholas Corcoran (Insider), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Gerardo Hernandez (CFO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), Miriam Provost (VP), Anil Ranganath (Insider), and David Weill (Director). Learn More on TransMedics Group's active insiders.
Are insiders buying or selling shares of TransMedics Group?: In the last year, insiders at the sold shares 14 times. They sold a total of 41,685 shares worth more than $5,663,249.30. The most recent insider tranaction occured on March, 4th when CFO Gerardo Hernandez sold 7,236 shares worth more than $1,065,211.56. Insiders at TransMedics Group own 7.0% of the company. Learn More about insider trades at TransMedics Group.
Information on this page was last updated on 3/4/2026.

Nicholas Corcoran Insider Trading History at TransMedics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/2/2026	Sell	2,966	$139.12	$412,629.92	29,831
8/27/2024	Sell	10,000	$176.02	$1,760,200.00	21,105
5/6/2024	Sell	3,222	$129.91	$418,570.02	21,105

Nicholas Corcoran Buying and Selling Activity at TransMedics Group

TransMedics Group Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Today's Range

Now: $114.00

$109.97

$115.00

50 Day Range

MA: $123.84

$94.31

$148.00

2 Week Range

Now: $114.00

$75.50

$156.00

Volume

820,963 shs

Average Volume

972,351 shs

Market Capitalization

$3.91 billion

P/E Ratio

23.27

Dividend Yield

N/A

Beta

2.09